SCHEMBL6468173

SCHEMBL6468173

COc1ccc(Cl)cc1-c1ccc(-n2cc(NC(N)=O)c(C(N)=O)n2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 1/20 0.44
KMT2A Q03164 6/20 0.44
POLB P06746 3/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
MAPT P10636 1/20 0.43
ALDH1A1 P00352 1/20 0.43
HPGD P15428 1/20 0.43
MEN1 O00255 5/20 0.43
TDP1 Q9NUW8 1/20 0.43
KDM4E B2RXH2 1/20 0.41
ITK Q08881 1/20 0.41
AURKA O14965 2/20 0.41
MAPKAPK2 P49137 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
ABL1 P00519 1/20 0.39
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
TYK2 P29597 1/20 0.39
JAK3 P52333 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6506967 0.89 PDE4D (0.51) PDE4DKMT2APOLBMAPTALDH1A1
SCHEMBL6499913 0.88 LRRK2 (0.46) KMT2APOLBMAPTALDH1A1HPGD
SCHEMBL6506528 0.86 KMT2A (0.46) KMT2APOLBCTDSP1MAPTALDH1A1
SCHEMBL6498654 0.86 MAPT (0.42) KMT2AMAPTALDH1A1HPGDMEN1
SCHEMBL6499612 0.84 MARS1 (0.44) KMT2AMAPTALDH1A1HPGDKDM4E
SCHEMBL6468677 0.83 MEN1 (0.47) KMT2APOLBCTDSP1MAPTALDH1A1
SCHEMBL6500313 0.83 ITK (0.47) KMT2APOLBALDH1A1HPGDMEN1
SCHEMBL6468745 0.82 KMT2A (0.44) KMT2APOLBMAPTALDH1A1HPGD
SCHEMBL6465833 0.81 ALDH1A1 (0.53) KMT2APOLBCTDSP1MAPTALDH1A1
SCHEMBL6470360 0.81 ITK (0.43) KMT2APOLBCTDSP1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197338-A1 Substituted pyrazole urea compounds for the treatment of inflammation PHARMACIA AND UPJOHN COMPANY LLC 2005-09-08 US disclosed
WO-2005037797-A1 SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197338-A1 Substituted pyrazole urea compounds for the treatment of inflammation IL4, ARG2, CASP4 PDE4D 1581/4885KMT2A 3219/4885POLB 2941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.